An observational study in Cardiogenic Shock, sponsored by Tufts Medical Center. Recruiting at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Tufts Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Shock, Cardiogenic with a site in United States — 19 open to participants now, 23 under way, none of them phase 3. Shock, Cardiogenic · United States.
Among the 50 studies in Shock, Cardiogenic with a site in United States, this one is the 2nd largest by planned enrollment of the 25 observational ones that give a count, is one of 2 that started in 2017, is one of 25 observational ones, reaches primary completion later than 12 of the 22 other live ones, and was the 19th registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →19 of the 50 studies in Shock, Cardiogenic with a site in United States are open now. Recruiting first, the newest first:
Abiomed Inc. · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 18+
Thomas Jefferson University · Sites in United States
Ages 18+
Atlantic Health System · Sites in United States
Ages 18–100
Abiomed Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 1 · Phase 4 3
First in 2005; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20,000 is above the median of 200 across 156 observational studies indexed under Shock, Cardiogenic.
Median enrollment 30 across the 25 interventional studies, 124 across the 25 observational. Of the 20 that completed or were terminated, 6 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 50 have an industry lead sponsor. The 10 most frequent:
Tufts Medical Center is the lead sponsor of 200 studies on the registry; 27 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 16 (48%) have results posted.
Tufts Medical Center has 3 studies filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
11 of the studies in Shock, Cardiogenic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05267886Ottawa Heart Institute Research CorporationCAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock | 2026-12 |
| NCT05800951Henry Ford Health SystemCan Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock | 2026-12-31 |
| NCT06253104Tufts Medical CenterChanges in Skeletal Muscle Thickness in Patients With Acute Heart Failure | 2026-12-31 |
| NCT07402018Thomas Jefferson UniversityIntra-aortic Balloon Counterpulsation (IABC) Compliance | 2026-12-31 |
| NCT07825363NIRSense Inc.Clinical Evaluation of NIRSense Tissue Oximetry Sensor Monitoring to Early Detect Cardiogenic Shock | 2027-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 50 studies in Shock, Cardiogenic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Cardiogenic Shock Working Group is a multicenter registry where we collect de-identified clinical variables from the medical records and follow-up phone calls of shock patients from multiple institutions and centralize this data to a single registry for analysis of clinical outcomes.
The Cardiogenic Shock Working Group is an Academic Research Consortium involving multiple medical centers within the United States and includes a multicenter registry for patients with cardiogenic shock. De-identified clinical variables are collected from medical records and follow-up phone calls. There is currently no central database for cardiogenic shock, therefore analysis of cardiogenic shock on a larger scale is limited. A goal of the Cardiogenic Shock Working Group is to create a centralized registry, compiled of data from multiple institutions, to analyze clinical outcomes. The Cardiogenic Shock Working Group Registry will include a retrospective arm, where data is collected during the course of the hospital stay, and a prospective arm, where long-term outcomes will be assessed.
People who are 18 or older who have an official diagnosis of cardiogenic shock.
Inclusion Criteria:
Cardiogenic shock is defined by at least one of the two categories below:
At least 2 of the following concurrently at any point during the index hospitalization:
Post-cardiotomy patients must meet the inclusion criteria 72 hours after their surgery to be included in this registry.
Cardiogenic Shock patients eligible for this study are defined by at least one of the two categories below. 1. Patients have at least 2 of the following concurrently at any point during the index hospitalization: MAP \< 60mmHg or a \>30mmHg drop in MAP from baseline, SBP \< 90mmHg or a \>30mmHg drop in SBP from baseline, Pulse \> 100, Cardiac Index \< 2.2, Cardiac Power Output ≤ 0.6 or PAPI \< 1.0. 2. Patients require the use of at least 1 vasopressor, inotrope or acute mechanical circulatory support device to maintain values above the above targets.
Drug: Vasopressor · Drug: Inotrope · Device: Acute Mechanical Circulatory Support Devices
The vasopressors include phenylephrine, norepinephrine, epinephrine, dopamine and vasopressin.
Inotropes include dobutamine and milrinone.
Acute Mechanical Circulatory Support devices include ECMO (VV), ECMO (VA), Impella CP, Impella 2.5, Impella 5.0, Impella 5.5, Impella RP, IABP, Centrimag, Tandem Heart and ProTek Duo.
Rate of Mortality
Death in subjects during the time frame.
Time frame: 30 days after discharge
Rate of Mortality
Death in subjects during the time frame.
Time frame: 1 year after discharge
Rate of Re-hospitalization
We will be observing if patient was hospitalized again during the 1 year-time frame. We will collect information on surgeries and interventions during the course of rehospitalization.
Time frame: 30 day after discharge
Rate of Re-hospitalization
We will be observing if patient was hospitalized again during the 1 year-time frame. We will collect information on surgeries and interventions during the course of rehospitalization.
Time frame: 1 year after discharge
New York Heart Association (NYHA) Class
NYHA Classification provides a way to classify the stages of heart failure. Class I- No symptoms and no limitation in ordinary physical activity Class II- Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity Class IV - Severe limitations
Time frame: 30 day after discharge
New York Heart Association (NYHA) Class
NYHA Classification provides a way to classify the stages of heart failure. Class I- No symptoms and no limitation in ordinary physical activity Class II- Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity Class IV - Severe limitations
Time frame: 1 year after discharge
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
Started Dec 2017 (actual). Primary completion is estimated for Dec 2027, 120 months after the start.
Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 120 months is above that.
Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Jan 2026 → Dec 2027 and completion Jun 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.